Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: a Meta-Analysis and Call to Action

J Cardiovasc Transl Res. 2022 Apr;15(2):258-267. doi: 10.1007/s12265-021-10158-0. Epub 2021 Jul 19.

Abstract

Venoarterial extracorporeal membrane oxygenation (ECMO) has been used to treat acute massive pulmonary embolism (PE) patients. However, the incremental benefit of ECMO to standard therapy remains unclear. Our meta-analysis objective is to compare in-hospital mortality in patients treated for acute massive PE with and without ECMO. The National Library of Medicine MEDLINE (USA), Web of Science, and PubMed databases from inception through October 2020 were searched. Screening identified 1002 published articles. Eleven eligible studies were identified, and 791 patients with acute massive PE were included, of whom 270 received ECMO and 521 did not. In-hospital mortality was not significantly different between patients treated with vs. without ECMO (OR = 1.24 [95% CI, 0.63-2.44], p = 0.54). However, these findings were limited by significant study heterogeneity. Additional research will be needed to clarify the role of ECMO in massive PE treatment. In-hospital mortality for patients with acute massive pulmonary embolism was not significantly different (OR of 1.24, p = 0.54) between those treated with and without venoarterial ECMO.

Keywords: Massive or high-risk pulmonary embolism; Venoarterial extracorporeal membrane oxygenation.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Extracorporeal Membrane Oxygenation* / adverse effects
  • Hospital Mortality
  • Humans
  • Pulmonary Embolism* / diagnosis
  • Pulmonary Embolism* / therapy
  • Retrospective Studies